What Oncocyte (IMDX) Said on Its Q3 Earnings Call

Insight Molecular Diagnostics (IMDX) expects to respond before a January 2027 deadline to the U.S. Food and Drug Administration’s request for more information about its GraftAssureDx kidney transplant test, executives said on the company’s third-quarter earnings call.

President and CEO Josh Riggs said the company is completing an independent accuracy study and an additional review of biopsy slides to support its De Novo submission. Both processes are expected to finish by the end of 2026, ahead of the Jan. 21 response deadline.

The company also has begun enrolling patients in its GALACTIC registry, which Riggs said should generate revenue and introduce clinicians to GraftAssure. He cautioned, however, that near-term revenue from the registry and beta-site program would be limited.

FDA Seeks More Clinical Information

The FDA completed the first phase of its substantive review in late July and requested additional information. During the analyst question-and-answer session, Riggs addressed a statement in the company’s release that the agency’s preliminary view was that the submitted clinical data did not yet support the proposed intended use.

Riggs said the initial submission included about 75 samples and that the FDA wanted more subgroup analysis and additional studies. The company now has roughly three times as many samples available, he said, and does not expect to conduct a new, broader study to respond.

The FDA also sought a more extensive review of biopsy slides than the local pathologist review included in the original submission, Riggs said. The company has secured two expert pathologists for the additional review.

The FDA’s review clock has been paused since the agency requested more information. Riggs estimated that approximately half of the agency’s targeted 150-day review period remains and said the clock would restart when the company submits its response. He noted that the FDA could take longer than the remaining targeted period.

If the company misses the Jan. 21 deadline, it would have to resubmit and restart the 150-day clock, Riggs said. He added that the company expects to launch shortly after any authorization because it is already manufacturing the same product for research use.

Registry and Hospital Testing Plans

UCLA was the first site to enroll patients in GALACTIC, and Riggs expects approximately five sites to be enrolling by year-end, with more anticipated in the first quarter of 2027. The registry aims to demonstrate a positive predictive value above 80% and a higher rate of biopsies that identify rejection, he said.

The company has also supported U.S. beta sites for about a year and a half. Riggs said several hospital laboratories have completed analytical and clinical validation and are working toward reimbursement. Centers representing more than one in 20 U.S. kidney transplants have indicated they are committed to in-house testing and preparing to launch in 2027, according to the company’s count.

Asked to quantify revenue from the registry and beta sites before a kidney test launch, Riggs said it would be “some, but not much.” He said the registry will initially send samples to the company, while a later phase would allow participating centers to run tests themselves. “We want to be in the kit business. We do not really want to be in the lab business,” he said.

Expenses and Reimbursement Strategy

CFO Andrea James said operating expenses and free cash flow moved in the right direction during the third quarter as FDA program costs declined. Research and development expenses were $3.8 million in the quarter, down from a peak of $5.8 million in the fourth quarter of 2025, she said. The company did not provide total revenue or earnings figures on the call.

James said the company has had Medicare MolDX reimbursement for its Tennessee lab-developed test since August 2023 and expects FDA authorization to allow it to transfer that reimbursement to customer labs. Riggs said the initial launch would focus on approximately 67 centers in MolDX jurisdictions that perform more than 50 kidney transplants annually.

Outside those jurisdictions, reimbursement requires additional work with Medicare administrative contractors. James said the company hopes to have a nationwide price and code in 2028 and is exploring ways to accelerate that process.

Heart and European Plans

Beyond kidney testing, Riggs said the company has added urine screening for T-cell-mediated rejection to its pipeline and is pursuing heart transplant testing. He said the company hopes to obtain the heart samples it needs in the first half of 2027, potentially supporting a submission late in the second half, though he emphasized that the company had not issued formal guidance.

In Europe, the company expects to submit kidney and heart applications around year-end or early January. Riggs said the review could take about six months but noted that broad reimbursement remains unavailable and limits commercialization.

About Oncocyte (NASDAQ:IMDX)

Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.